SPY415.21-2.05 -0.49%
DIA340.75-1.11 -0.32%
IXIC13,914.77-137.58 -0.98%

BRIEF-Arbutus Receives Regulatory Approval To Initiate A Phase 1A/1B Clinical Trial With AB-836, An Oral Capsid Inhibitor For The Treatment Of Chronic Hepatitis B Infection

· 03/16/2021 07:39
BRIEF-Arbutus Receives Regulatory Approval To Initiate A Phase 1A/1B Clinical Trial With AB-836, An Oral Capsid Inhibitor For The Treatment Of Chronic Hepatitis B Infection

- Arbutus Biopharma Corp ABUS.O:

  • ARBUTUS RECEIVES REGULATORY APPROVAL TO INITIATE A PHASE 1A/1B CLINICAL TRIAL WITH AB-836, AN ORAL CAPSID INHIBITOR FOR THE TREATMENT OF CHRONIC HEPATITIS B INFECTION

Source text for Eikon: ID:nGNXZqry8

Further company coverage: ABUS.O


((Reuters.Briefs@thomsonreuters.com;))